Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

465 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.
Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, Kavanaugh A, Landewé R, Mease P, Sieper J, Stamm T, Wit M, Aletaha D, Baraliakos X, Betteridge N, Bosch FVD, Coates LC, Emery P, Gensler LS, Gossec L, Helliwell P, Jongkees M, Kvien TK, Inman RD, McInnes IB, Maccarone M, Machado PM, Molto A, Ogdie A, Poddubnyy D, Ritchlin C, Rudwaleit M, Tanew A, Thio B, Veale D, Vlam K, van der Heijde D. Smolen JS, et al. Among authors: baraliakos x. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Ann Rheum Dis. 2018. PMID: 28684559 Free PMC article.
Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks.
Marzo-Ortega H, Mease PJ, Rahman P, Navarro-Compán V, Strand V, Dougados M, Combe B, Wei JC, Baraliakos X, Hunter T, Sandoval D, Li X, Zhu B, Bessette L, Deodhar A. Marzo-Ortega H, et al. Among authors: baraliakos x. Rheumatol Ther. 2020 Dec;7(4):759-774. doi: 10.1007/s40744-020-00225-4. Epub 2020 Aug 19. Rheumatol Ther. 2020. PMID: 32814997 Free PMC article.
Correspondence on 'No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related 'physician-reported spondylitis'?'.
Gladman DD, Mease PJ, Bird P, Soriano ER, Chakravarty SD, Shawi M, Lavie F, Gong C, Leibowitz E, Poddubnyy D, Tam LS, Helliwell PS, Kavanaugh A, Deodhar AA, Østergaard M, Baraliakos X. Gladman DD, et al. Among authors: baraliakos x. Ann Rheum Dis. 2023 Aug;82(8):e187. doi: 10.1136/annrheumdis-2022-222161. Epub 2022 Apr 29. Ann Rheum Dis. 2023. PMID: 35487679 No abstract available.
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
Gladman DD, Mease PJ, Bird P, Soriano ER, Chakravarty SD, Shawi M, Xu S, Quinn ST, Gong C, Leibowitz E, Poddubnyy D, Tam LS, Helliwell PS, Kavanaugh A, Deodhar A, Østergaard M, Baraliakos X. Gladman DD, et al. Among authors: baraliakos x. Trials. 2022 Sep 5;23(1):743. doi: 10.1186/s13063-022-06589-y. Trials. 2022. PMID: 36064592 Free PMC article.
Management of Axial Spondyloarthritis - Insights into Upadacitinib.
Braun J, Kiltz U, Baraliakos X. Braun J, et al. Among authors: baraliakos x. Drug Des Devel Ther. 2022 Oct 19;16:3609-3620. doi: 10.2147/DDDT.S330413. eCollection 2022. Drug Des Devel Ther. 2022. PMID: 36268520 Free PMC article. Review.
Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study.
Mease PJ, Gladman DD, Poddubnyy D, Chakravarty SD, Shawi M, Kollmeier AP, Xu XL, Xu S, Deodhar A, Baraliakos X. Mease PJ, et al. Among authors: baraliakos x. Rheumatol Ther. 2023 Dec;10(6):1637-1653. doi: 10.1007/s40744-023-00592-8. Epub 2023 Oct 11. Rheumatol Ther. 2023. PMID: 37819505 Free PMC article.
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies.
Mease PJ, Helliwell PS, Gladman DD, Poddubnyy D, Baraliakos X, Chakravarty SD, Kollmeier AP, Hsia EC, Xu XL, Sheng S, Agarwal P, Zhou B, Sweet K, Shawi M, Karyekar CS, Deodhar A, van der Heijde D. Mease PJ, et al. Among authors: baraliakos x. Lancet Rheumatol. 2021 Oct;3(10):e715-e723. doi: 10.1016/S2665-9913(21)00105-3. Epub 2021 Jun 29. Lancet Rheumatol. 2021. PMID: 38287608
465 results